Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jun 20;33(18):2112-8.
doi: 10.1200/JCO.2014.59.7203. Epub 2015 May 4.

Revised International Pediatric Non-Hodgkin Lymphoma Staging System

Angelo Rosolen  1 , Sherrie L Perkins  1 , C Ross Pinkerton  1 , R Paul Guillerman  1 , John T Sandlund  1 , Catherine Patte  1 , Alfred Reiter  1 , Mitchell S Cairo  2
Affiliations

Revised International Pediatric Non-Hodgkin Lymphoma Staging System

Angelo Rosolen et al. J Clin Oncol. .

Abstract

Purpose: Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in the last 30 years. However, the St Jude NHL staging classification for pediatric NHL was developed more than 35 years ago. The most recent Lugano lymphoma staging classification focused on adult lymphoma. Furthermore, major limitations of the current pediatric NHL staging classification include lack of consideration of new distinct pediatric NHL histologic entities; absence of recognition of frequent skin, bone, kidney, ovarian, and other organ involvement; and lack of newer precise methods to detect bone marrow and CNS involvement, minimal disease quantification, and highly sensitive imaging technologies.

Methods: An international multidisciplinary expert panel convened in Frankfurt, Germany, in 2009 at the Third International Childhood, Adolescent and Young Adult NHL Symposium to develop a revised international pediatric NHL staging system (IPNHLSS), addressing limitations of the current pediatric NHL staging system and creating a revised classification. Evidence-based disease distribution and behavior were reviewed from multiple pediatric cooperative group NHL studies.

Results: A revised IPNHLSS was developed incorporating new histologic entities, extranodal dissemination, improved diagnostic methods, and advanced imaging technology.

Conclusion: This revised IPNHLSS will facilitate more precise staging for children and adolescents with NHL and facilitate comparisons of efficacy across different treatment strategies, various institutions, multicenter trials, and cooperative groups by allowing for reproducible pediatric-based staging at diagnosis and relapse.

PubMed Disclaimer

Conflict of interest statement

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Figures

Fig 1.
Fig 1.
Survival analysis. Progression-free survival (PFS) analysis (A) in patients with Burkitt's lymphoma at high risk (Berlin-Frankfurt-Munster high-risk group R4) according to morphologic bone marrow (BM) status at diagnosis and (B) according to minimal disseminated disease (MDD) status in BM at diagnosis. Data adapted.
Fig 2.
Fig 2.
Event-free survival according to levels of T-cell lymphoblastic lymphoma (T-LL) cells in bone marrow at diagnosis measured by flow cytometry. Data adapted.
Fig 3.
Fig 3.
Outcome of patients with anaplastic large-cell lymphoma according to quantitative polymerase chain reaction (PCR) results for NPM-ALK in bone marrow. (A) Cumulative incidence of relapse and (B) Kaplan-Meier estimates of event-free survival of 74 patients with either negative qualitative bone marrow (BM) PCR or positive qualitative BM PCR using quantitative (quant) PCR results and NPM-ALK cutoff copy number of 10 of 104 copies of ABL (normalized copy number). NR, nonrelapse. Data adapted.
See this image and copyright information in PMC

Comment in

References

    1. Abromowitch M, Sposto R, Perkins S, et al. Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: Report from the Children's Oncology Group. Br J Haematol. 2008;143:261–267. - PMC - PubMed
    1. Brugières L, Le Deley MC, Rosolen A, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: Results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897–903. - PubMed
    1. Cairo MS, Gerrard M, Sposto R, et al. Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents. Blood. 2007;109:2736–2743. - PMC - PubMed
    1. Cairo MS, Sposto R, Hoover-Regan M, et al. Childhood and adolescent large-cell lymphoma (LCL): A review of the Children's Cancer Group experience. Am J Hematol. 2003;72:53–63. - PubMed
    1. Cairo MS, Sposto R, Perkins SL, et al. Burkitt's and Burkitt-like lymphoma in children and adolescents: A review of the Children's Cancer Group experience. Br J Haematol. 2003;120:660–670. - PubMed

Publication types